Redcare Pharmacy lifts FY 2026 revenue growth outlook to 16%-18%

• Redcare Pharmacy lifted full-year 2026 revenue guidance for a second time, citing sustained prescription-drug momentum in Germany.
• Total revenue growth now seen at 16% to 18%, up from 15% to 17%; non-Rx growth maintained at 10% to 12%.
• Germany Rx revenue forecast raised to EUR 730-760 million, implying 45% to 51% growth versus EUR 680-720 million previously.
• Adjusted EBITDA margin outlook kept at 2.5% to 3.0%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redcare Pharmacy NV published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2406332_en) on September 28, 2026, and is solely responsible for the information contained therein.